Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | ECE1 | P42892 | 7/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862463 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862452 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862460 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862455 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL9868128 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862445 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29577062 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29531119 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862461 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL30862439 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952433-B2 | Heterochiral peptide-complex and composition for measuring nuclear magnetic resonance spectroscopy residual dipolar coupling containing self-assembled intermediates of heterochiral peptide-complex | INDUSTRY ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2024-04-09 | — | — | US | claimed |
| US-11952433-B2 | Heterochiral peptide-complex and composition for measuring nuclear magnetic resonance spectroscopy residual dipolar coupling containing self-assembled intermediates of heterochiral peptide-complex | INDUSTRY ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2024-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952433-B2 | Heterochiral peptide-complex and composition for measuring nuclear magnetic resonance spectroscopy residual dipolar coupling containing self-assembled intermediates of heterochiral peptide-complex | HM13, PRRC2C, IAPP | ACE 4207/4885KDM4E 4812/4885MEN1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.